Turnstone Biologics TSBX, ,, a clinical stage biotech company that specializes on treatments for solid tumours, announced the terms of its IPO Monday. The plan is to offer 5,8 million shares at a price between $12 and $14 per share. At the upper end of this range, Turnstone Biologics would raise $81.2 at a $298 million valuation. The company is applying to list on Nasdaq with the ticker “TSBX”. BofA Securities and Leerink Partners are underwriting this deal. The proceeds will be used for the development of TIDAL-01 – a treatment that treats breast cancer, colorectal carcinoma, uveal melanomas and other noncutaneous and cutaneous melanoma – and for other programs. The Renaissance IPO ETF IPO -1.52% is up 41.4% year-to-date, while the S&P500 SPX -0.10% is up 17%.